MoxonidineAPO-Moxonidine
Recommended · restricted CardiovascularRestrictedNot applicable line
Treatment of hypertension as add-on therapy in patients receiving concurrent antihypertensive therapy, where a centrally acting agent is required.
2
Submissions
2 resub
2006–06
On the record
—
ICER range
Cost-min
Cost basis
Access path
- TGA registered · APO-Moxonidine
TGA label narrower than the PBS population
- Mar 2006Recommended · restricted
Comparator changed: clonidine → clonidine hydrochloride
- Mar 2006Recommended · restricted
Comparator changed: clonidine → clonidine hydrochloride
- PBS listing · Restricted
RecommendedDeferredNot recommended
Cost-effectiveness
Cost-minimisation analysis; no ICER calculated.
The PBAC considered the choice of a cost-minimisation approach valid. PBAC · 2006
Decision context
PopulationPatients with hypertension receiving concurrent antihypertensive therapy, where a centrally acting agent is required.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Mar 2006 | Recommended · restricted | clonidine | — | RCT · Other |
| Mar 2006 | Recommended · restricted | clonidine hydrochloride | — | RCT |
Similar precedents
Regulatory · TGA
Label narrower than PBS population — PBAC restricts to patients already receiving concurrent antihypertensive therapy (later-line), whereas TGA label permits treatment of hypertension generally.